2018 ASCO: Gender Disparities in Head and Neck Cancer Treatment and Outcomes

Key Points

  • The odds of receiving intensive chemotherapy were 35% for women vs 46% for men, and the odds of receiving radiation were 60% for women and 70% for men.
  • While both men and women were more likely to die of cancer than of other causes, the ratio of cancer deaths vs noncancer deaths was 1.92 times higher for women than for men.
  • Fewer women than men had oropharyngeal cancers (38% vs 55%). While further analysis is ongoing, this may also be a factor driving higher cancer-related mortality rates in women, as HPV-related cancers occur most frequently in the oropharynx. 

An analysis of cancer registry data from a California hospital system showed that women with head and neck cancer were less likely to receive intensive chemotherapy (35% vs 46%) and radiation (60% vs 70%) compared to men. Controlling for factors such as age and serious medical conditions, a mathematical model also shows that the ratio of cancer to noncancer mortality was two times higher for women than the ratio for men.

When taken collectively, the findings raise the possibility women with head and neck cancer may be undertreated. The authors explain that there are some confounding factors, so further prospective investigation is necessary to fully address this possibility. The study was featured in a press briefing today and presented by Katzel et al at the 2018 ASCO Annual Meeting (Abstract LBA6002).

“We weren’t looking for gender differences, so the results were really surprising. Besides undertreatment, there are a number of factors that could contribute to the differences in outcomes between women and men with head and neck cancer, and it’s clear we need further investigation,” said senior study author Jed A. Katzel, MD, a medical oncologist at Kaiser Permanente in Santa Clara, California. “With this mathematical model, we have a tool that can help us identify patients likely to benefit from more intensive treatment, as well as those more likely to die from other non–cancer-related causes. The hope is that by integrating this model into our care, we can improve the care of all patients with head and neck cancer.”

Head and neck cancers account for approximately 4% of all cancers in the United States and are more than twice as common among men as they are among women.

Treating Head and Neck Cancer

When considering treatment, oncologists take into account a patient’s activity level and other medical problems. Patients with head and neck cancer who have good performance status may be offered more intense treatments, including platinum-based chemotherapy with radiation therapy. Patients who cannot tolerate intensive chemotherapy may be offered less intensive treatments, such as targeted therapy with cetuximab (Erbitux) and radiation, radiation alone, or even no cancer treatment at all.

Another factor influencing head and neck cancer treatment and outcomes is whether the cancer is caused by the human papillomavirus (HPV). HPV-related head and neck tumors are more responsive to treatment, and people with such cancers generally have a better prognosis. HPV-related head and neck cancer is more common in men than in women. In the authors’ prior analysis of patients in Northern California, for example, they found that only about 22.6% of HPV-related cancers occurred in women, compared with 77.4% in men.

About the Study

Researchers evaluated health outcomes for 223 female and 661 male patients with stage II to IVB head and neck cancer treated at Kaiser Permanente Northern California. The odds of receiving intensive cancer treatment were estimated using logistic regression models and adjusting for factors such as age, gender, tumor stage, Charlson Comorbidity Index, and history of smoking and alcohol use.

A mathematical tool called the generalized competing event (GCE) model was used to compare the risk of dying from cancer to the risk of dying from other causes. The GCE model controls for differences in age, gender, tumor site, and Charlson score. In this analysis, the researchers did not control for differences in tumor type with respect to HPV status.

Key Findings

Overall, the study identified several differences by gender:

  • Treatment: The odds of receiving intensive chemotherapy were 35% for women vs 46% for men, and the odds of receiving radiation were 60% for women and 70% for men.
  • Mortality: At a median follow-up of 2.9 years, 271 patients died of cancer and 93 from other causes. While both men and women were more likely to die of cancer than of other causes, the ratio of cancer deaths to noncancer deaths was 1.92 times higher for women than for men.
  • HPV-related cancers: Fewer women than men had oropharyngeal cancers (38% vs 55%). While further analysis is ongoing, this may also be a factor driving higher cancer-related mortality rates in women, as HPV-related cancers occur most frequently in the oropharynx.

Next Steps

Researchers plan to conduct a more detailed review of treatments that women in the study received. They’re also interested in determining causes for the gender differences in survival, such as if the findings reflect the difference in the rate of HPV-related head and neck cancers between women and men. Additionally, “the GCE model will be further evaluated in the NRG-HN004 trial that is currently enrolling patients,” said Dr. Katzel. “It is a trial that we will be participating in.”

This study received funding from Kaiser Permanente Norther California Graduate Medical Education Department.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.